INTERLEUKIN-1 RECEPTOR ANTAGONIST BLOCKS SOMNOGENIC AND PYROGENIC RESPONSES TO AN INTERLEUKIN-1 FRAGMENT

被引:52
|
作者
OPP, MR
POSTLETHWAITE, AE
SEYER, JM
KRUEGER, JM
机构
[1] UNIV TENNESSEE CTR HLTH SCI,DEPT PHYSIOL & BIOPHYS,MEMPHIS,TN 38163
[2] UNIV TENNESSEE CTR HLTH SCI,DEPT MED,MEMPHIS,TN 38163
[3] UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163
[4] VET ADM MED CTR,MEMPHIS,TN 38104
关键词
SLEEP; FEVER; RAT; RABBIT; BEHAVIOR;
D O I
10.1073/pnas.89.9.3726
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Previously it was shown that human interleukin 1 (huIL-1) and a huIL-1 fragment, huIL-1-beta-208-240, are somnogenic and pyrogenic in rabbits. However, the amino acid sequences for IL-1 are species-specific and it was unknown whether rabbit (rb) IL-1-beta-208-240 and rat (rt) IL-1-beta-208-240 were active in their respective species. Furthermore, it was unknown whether these fragments elicited their effects via the IL-1 receptors. Two doses of rbIL-1-beta-208-240 (6.0 and 12.0 nmol) were intracerebroventricularly administered to rabbits The 6.0-nmol dose had little effect, whereas the 12.0-nmol dose greatly increased non-rapid-eye-movement sleep across a 6-hr recording period and induced a febrile response. Rats injected intracerebroventricularly with rtIL-1-beta-208-240 at dark onset responded to three doses of the peptide (1.2, 2.4, and 4.8 nmol). The 1.2-nmol dose did not greatly affect sleep but did induce a moderate febrile response. The 2.4- and 4.8-nmol doses increased non-rapid-eye-movement sleep across the 12-hr recording period. Maximal brain temperature elevations relative to controls after the 2.4- and 4.8-nmol doses of the peptide were 0.9 +/- 0.2-degrees-C and 0.7 +/- 0.2-degrees-C, respectively. These responses in both rabbits and rats were completely blocked or significantly attenuated when the animals were pretreated with an IL-1 receptor antagonist. These results suggest that the biological activities of IL-1-beta-208-240 are mediated via the IL-1-beta-receptors.
引用
收藏
页码:3726 / 3730
页数:5
相关论文
共 50 条
  • [21] INTERLEUKIN-1 RECEPTOR ANTAGONIST INHIBITS THE HYPERCALCEMIA MEDIATED BY INTERLEUKIN-1
    GUISE, TA
    GARRETT, IR
    BONEWALD, LF
    MUNDY, GR
    JOURNAL OF BONE AND MINERAL RESEARCH, 1993, 8 (05) : 583 - 587
  • [22] Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease
    Cominelli, F
    Pizarro, TT
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 : 49 - 53
  • [23] Interleukin-1α, interleukin-1β and interleukin-1 receptor antagonist share a common U-shaped recognition epitope on interleukin-1 receptor surface
    Ma, Huaijun
    Liu, Jie
    Wu, Wei
    He, Ping
    JOURNAL OF MOLECULAR RECOGNITION, 2022, 35 (09)
  • [24] INTERLEUKIN-1 RECEPTOR ANTAGONIST COMPETITIVELY INHIBITS THE BINDING OF INTERLEUKIN-1 TO THE TYPE-II INTERLEUKIN-1 RECEPTOR
    GRANOWITZ, EV
    CLARK, BD
    MANCILLA, J
    DINARELLO, CA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (22) : 14147 - 14150
  • [25] INTERLEUKIN-1 RECEPTOR ANTAGONIST COMPETITIVELY INHIBITS THE BINDING OF INTERLEUKIN-1 TO THE TYPE-II INTERLEUKIN-1 RECEPTOR
    GRANOWITZ, EV
    MANCILLA, J
    CLARK, BD
    DINARELLO, CA
    CLINICAL RESEARCH, 1991, 39 (02): : A462 - A462
  • [26] Localisation of mRNA for interleukin-1 receptor and interleukin-1 receptor antagonist in the rat ovary
    Wang, LJ
    Brannstrom, M
    Cui, KH
    Simula, AP
    Hart, RP
    Maddocks, S
    Norman, RJ
    JOURNAL OF ENDOCRINOLOGY, 1997, 152 (01) : 11 - 17
  • [27] RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST BLOCKS THE PROINFLAMMATORY ACTIVITY OF ENDOGENEOUS INTERLEUKIN-1 IN RABBIT IMMUNE COLITIS
    COMINELLI, F
    NAST, CC
    DUCHINI, A
    LEE, M
    GASTROENTEROLOGY, 1992, 103 (01) : 65 - 71
  • [28] COMPARATIVE RESPONSES OF HUMAN AND RABBIT INTERLEUKIN-1 INVIVO - EFFECT OF A RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST
    VONUEXKULL, C
    NOURSHARGH, S
    WILLIAMS, TJ
    IMMUNOLOGY, 1992, 77 (04) : 483 - 487
  • [29] Interleukin-1β, Interleukin-1 Receptor Antagonist, and Soluble Interleukin-1 Receptor Type II Secretion in Chronic Fatigue Syndrome
    Joseph G. Cannon
    Jonathan B. Angel
    Leslie W. Abad
    Edouard Vannier
    Maria D. Mileno
    Laura Fagioli
    Sheldon M. Wolff
    Anthony L. Komaroff
    Journal of Clinical Immunology, 1997, 17 : 253 - 261
  • [30] ROLE OF INTERLEUKIN-1 AND THE THERAPEUTIC POTENTIAL OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN SEPSIS
    FISHER, CJ
    OPAL, SM
    LOWRY, SF
    SADOFF, JC
    LABRECQUE, JF
    DONOVAN, HC
    LOOKABAUGH, JL
    LEMKE, J
    PRIBBLE, JP
    STROMATT, SC
    VIGERS, GP
    RUSSELL, DA
    THOMPSON, RC
    CIRCULATORY SHOCK, 1994, 44 (01) : 1 - 8